Regeneron Pharmaceuticals, Inc. REGN
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 5.23% | -2.91% | -1.69% | 2.09% | -1.64% |
| Total Depreciation and Amortization | -2.32% | 3.63% | 8.94% | 12.59% | 11.84% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 208.62% | -929.91% | -246.23% | -520.31% | -66.75% |
| Change in Net Operating Assets | -326.53% | 107.32% | 147.30% | 186.14% | 174.21% |
| Cash from Operations | -4.44% | -1.31% | 26.80% | 12.63% | 19.39% |
| Capital Expenditure | -20.06% | -3.50% | -5.69% | -18.85% | -5.15% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -100.00% |
| Cash Acquisitions | 97.93% | 71.30% | 80.00% | 80.00% | -64.77% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 17.97% | -4.76% | -212.36% | 115.89% | 117.48% |
| Cash from Investing | -18.16% | -5.06% | -1,177.53% | 74.51% | 82.71% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 355.31% | 72.74% | -12.49% | -56.60% | -86.67% |
| Repurchase of Common Stock | 6.87% | 6.96% | 6.20% | -9.31% | -27.06% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -37.97% | -103.06% | -299.04% | -- | -- |
| Other Financing Activities | 100.00% | 100.00% | 100.00% | 69.16% | 69.16% |
| Cash from Financing | 23.92% | 11.59% | -2.75% | -68.84% | -169.39% |
| Foreign Exchange rate Adjustments | -900.00% | -272.73% | -400.00% | 142.86% | -150.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 131.10% | 415.33% | -125.33% | 355.10% | 437.80% |